Subject(s)
Hospitalization/economics , Schizophrenia/rehabilitation , Schizophrenic Psychology , Adult , Cost-Benefit Analysis , Deinstitutionalization/economics , Female , Follow-Up Studies , Humans , Long-Term Care/economics , Male , Psychiatric Department, Hospital/economics , Quality Assurance, Health Care/economics , Rehabilitation, Vocational/economics , Rehabilitation, Vocational/psychology , Schizophrenia/economics , SwitzerlandSubject(s)
Depressive Disorder/drug therapy , Iproniazid/therapeutic use , Monoamine Oxidase Inhibitors/therapeutic use , Phobic Disorders/drug therapy , Adult , Depressive Disorder/psychology , Dose-Response Relationship, Drug , Drug Administration Schedule , Female , Follow-Up Studies , Humans , Iproniazid/adverse effects , Male , Middle Aged , Monoamine Oxidase Inhibitors/adverse effects , Phobic Disorders/psychology , RecurrenceABSTRACT
In an open, clinical trial comprising a total of 49 depressed in-patients, a new selective 5-HT uptake inhibitor citalopram was administered by intravenous infusion in doses of 20-60 mg once daily for per 3 weeks. The therapeutic effect was assessed globally and by means of the CPRS subscale for depression (MADRS). About 40 per cent of the patients showed a complete response whereas about 25 per cent showed a partial response. Side effects which were rated globally and recorded according to a check-list were generally mild and infrequent. The side-effects most frequently observed were tremor, drowsiness, and dizziness which occurred in about 15 per cent of the patients.' Three patients were withdrawn prematurely because of nausea and one because of a skin rash. Cardiovascular recordings were normal except for one patient, who developed a hypertension which may have been related to the test drug. No pathological laboratory values were detected during the trial period. The authors conclude that intravenously administered citalopram is well suited for the treatment of depressed patients.